REFERENCES
1. World Health Organization. Influenza (Seasonal). World Health Organization.
2. Takashita E, Daniels RS, Fujisaki S, et al. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017–2018.Antiviral Res . 2020;175(January). doi:10.1016/j.antiviral.2020.104718
3. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. J Am Med Assoc . 2006;295(8):891-894. doi:10.1001/jama.295.8.joc60020
4. Hurt AC. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol . 2014;8:22-29. doi:10.1016/j.coviro.2014.04.009
5. Hauge SH, Blix HS, Borgen K, Hungnes O, Dudman SG, Aavitsland P. Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. Virol J . 2009;6:4-7. doi:10.1186/1743-422X-6-54
6. Butler J, Hooper KA, Petrie S, et al. Estimating the Fitness Advantage Conferred by Permissive Neuraminidase Mutations in Recent Oseltamivir-Resistant A(H1N1)pdm09 Influenza Viruses. PLoS Pathog . 2014;10(4). doi:10.1371/journal.ppat.1004065
7. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med . 2018;379(10):913-923. doi:10.1056/NEJMoa1716197
8. Ison MG, Portsmouth S, Yoshida Y, et al. Baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza.Lancet Infect Dis ., in press.
9. Noshi T, Kitano M, Taniguchi K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res . 2018;160(October):109-117. doi:10.1016/j.antiviral.2018.10.008
10. Omoto S, Speranzini V, Hashimoto T, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep . 2018;8(1):1-15. doi:10.1038/s41598-018-27890-4
11. Stevaert A, Dallocchio R, Dessi A, et al. Mutational Analysis of the Binding Pockets of the Diketo Acid Inhibitor L-742,001 in the Influenza Virus PA Endonuclease. J Virol . 2013;87(19):10524-10538. doi:10.1128/jvi.00832-13
12. Pflug A, Lukarska M, Resa-infante P, Reich S, Cusack S. Structural insights into RNA synthesis by the influenza virus transcription-replication machine. Virus Res . 2017;234:103-117. doi:10.1016/j.virusres.2017.01.013
13. Mishin VP, Patel MC, Chesnokov A, et al. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir 1. 2019;25(10):1969-1972.
14. Peng Q, Liu Y, Peng R, et al. Structural insight into RNA synthesis by influenza D polymerase. Nat Microbiol . 2019;4(10):1750-1759. doi:10.1038/s41564-019-0487-5
15. Uehara T, Hayden FG, Kawaguchi K, et al. Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza. J Infect Dis . 2020;221(3):346-355. doi:10.1093/infdis/jiz244
16. Takashita E, Kawakami C, Ogawa R, et al. Influenza a(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019.Eurosurveillance . 2019;24(12):1-4. doi:10.2807/1560-7917.ES.2019.24.12.1900170
17. Takashita E, Ichikawa M, Morita H, et al. Human-to-human transmission of influenza A(H3N2) virus with reduced susceptibility to baloxavir, Japan, February 2019. Emerg Infect Dis . 2019;25(11):2108-2111. doi:10.3201/eid2511.190757
18. Imai M, Yamashita M, Sakai-Tagawa Y, et al. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets. Nat Microbiol . 2019:1-7. doi:10.1038/s41564-019-0609-0
19. Gubareva L V., Mishin VP, Patel MC, et al. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Eurosurveillance . 2019;24(3):9-13. doi:10.2807/1560-7917.ES.2019.24.3.1800666
20. Ince WL, Smith FB, O’Rear JJ, Thomson M. Treatment-emergent influenza virus PA substitutions independent of those at I38 associated with reduced baloxavir susceptibility and virus rebound in trials of baloxavir marboxil. J Infect Dis . 2020;(1):1-5. doi:10.1093/infdis/jiaa164
21. McAuley JL, Gilbertson BP, Trifkovic S, Brown LE, McKimm-Breschkin JL. Influenza virus neuraminidase structure and functions. Front Microbiol . 2019;10(JAN). doi:10.3389/fmicb.2019.00039
22. Goldhill DH, Te Velthuis AJW, Fletcher RA, et al. The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci U S A . 2018;115(45):11613-11618. doi:10.1073/pnas.1811345115
23. Watanabe A, Ishida T, Hirotsu N, et al. Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study. Antiviral Res . 2019;163(January):75-81. doi:10.1016/j.antiviral.2019.01.012
24. Hirotsu N, Sakaguchi H, Sato C, et al. Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes. Clin Infect Dis . 2019:1-11. doi:10.1093/cid/ciz908
25. Chesnokov A, Patel MC, Mishin VP, et al. Replicative Fitness of Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir.J Infect Dis . 2020;221(3):367-371. doi:10.1093/infdis/jiz472
26. Sato M, Takashita E, Katayose M, et al. Detection of Variants With Reduced Baloxavir Marboxil Susceptibility After Treatment of Children With Influenza A During the 2018–2019 Influenza Season. J Infect Dis . 2020;(Xx Xxxx):1-5. doi:10.1093/infdis/jiaa061
27. Ahmed AR. H1N1 with fatal viral septicemia in a normal child: A case report. Respir Med Case Reports . 2020;30:101055. doi:10.1016/j.rmcr.2020.101055